Adjuvant therapy ‘cuts risk of brain metastases’ in NSCLC
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
In people with resectable non-small cell lung cancer (NSCLC) who have a mutated epidermal growth factor receptor gene (EGFR), adjuvant osimertinib reduces the risk of a brain metastasis within 18 months to below 1%, trial results show.
Delegates at the European Society for Medical Oncology (ESMO) virtual congress 2020 were told about an exploratory analysis of results from the ADAURA trial of osimertinib, an EGFR tyrosine kinase inhibitor.
In the trial, 682 patients with EGFR-mutated, resectable NSCLC (stages IB to IIIA) were treated with adjuvant osimertinib (80 mg/day) or placebo until recurrence or for a maximum of three years, Dr Masahiro Tsuboi of the National Cancer Centre Hospital East, Chiba, Japan, told congress delegates.
